When a Bone Marrow Transplant Is Considered for Marrow Failure and How Donors Are Matched

The hematologist slides a sheet of blood counts across the desk and circles three numbers. None of them is where it should be. Then comes the sentence that changes the shape of the conversation: “We should talk about whether a transplant makes sense for you.” For most people, that word lands with a jolt. Transplant sounds like something that happens to other patients, in other stories.

Bone marrow transplant marrow failure eligibility is not a single yes-or-no test. It is a weighing of how badly the marrow has stopped working, how strong the rest of the body is, and whether a suitable donor exists. Those three questions get answered in a particular order, and understanding that order takes much of the mystery out of the weeks ahead.

This explainer walks through when a transplant comes onto the table for marrow failure, who tends to be offered one, who is asked to try something else first, and how the search for a matching donor actually works.

What is marrow failure, and why does a transplant come up?

Bone marrow is the soft tissue inside the large bones that manufactures blood: red cells to carry oxygen, white cells to fight infection, and platelets to stop bleeding. Marrow failure means the factory has slowed or shut down, so one or more of those cell lines falls too low to keep the body safe. The National Heart, Lung, and Blood Institute describes the most common acquired form, aplastic anemia, as a condition in which the marrow stops making enough of all three cell types.

The causes split into two broad families. Acquired marrow failure most often follows an immune attack on the marrow’s stem cells, sometimes triggered by a virus, a medicine, a chemical exposure, or no identifiable event at all. Inherited marrow failure syndromes, such as Fanconi anemia or dyskeratosis congenita, come from gene changes present from birth and tend to declare themselves in childhood or early adulthood.

Why does a transplant enter the picture? Because the problem sits in the stem cells themselves. Transfusions replace red cells and platelets for a few days or weeks, and growth factors can nudge a struggling marrow, but neither fixes the underlying supply. A transplant replaces the failing stem cells with healthy ones from a donor, which then take up residence in the marrow and, if all goes well, start producing blood. That is the whole idea, and it is why the procedure is reserved for people whose marrow is unlikely to recover on its own.

Two facts matter most at this early stage. First, marrow failure is not marrow cancer; the stem cells have stopped working rather than multiplied out of control, even though some marrow failure conditions carry a raised risk of later blood cancers. Second, not every person with low counts is headed for transplant. Many are watched, transfused, or treated with medicines that calm the immune system, and the transplant discussion is one branch of a wider decision tree.

How a bone marrow transplant for marrow failure actually works

Strip away the jargon and the procedure has four movements. A donor’s healthy blood-forming stem cells are collected. The recipient receives conditioning treatment, meaning chemotherapy and sometimes low-dose radiation, to clear space in the marrow and suppress the immune system so it will not reject the incoming cells. The donor cells are then given through a vein, much like a transfusion, and they find their own way to the marrow. Finally the team waits, watching daily blood tests for the first signs that the new cells have settled in and started to work, a milestone called engraftment.

The transplant itself, the infusion, is usually the least dramatic part. MedlinePlus notes that the cells travel through the bloodstream to the bone marrow, where they begin to grow and produce new blood cells over the following weeks. There is no surgery on the recipient’s bones. The name is historical: early transplants drew cells directly from the donor’s pelvic bone, and although stem cells can now also be collected from circulating blood or umbilical cord blood, the phrase stuck. Many teams now say “stem cell transplant,” and the terms are used interchangeably.

For marrow failure the transplant is allogeneic, a word meaning the cells come from another person rather than from the patient. That distinction matters. A person’s own stem cells are the problem in marrow failure, so returning them would return the disease. Using donor cells also means the new immune system arrives with the new marrow, which explains both the main risk of the procedure, graft-versus-host disease, and the reason matching is so carefully done.

The days before infusion are conventionally numbered in negatives, counting down through conditioning. Infusion day is “day zero,” and everything afterward is counted upward. Patients quickly learn to speak this language, and it helps to know it before the first consultation.

Bone marrow transplant for marrow failure: who is usually eligible?

Eligibility is a clinical judgment rather than a checklist, but transplant teams tend to look at the same handful of factors. The first is severity. Guidelines distinguish severe and very severe aplastic anemia from milder forms by how low the neutrophil, platelet and reticulocyte counts have fallen and how empty the marrow looks on biopsy. The lower those counts and the more often transfusions are needed, the stronger the case for definitive treatment.

The second factor is age and general health. Younger people typically tolerate conditioning better and have lower rates of serious complications, which is why transplant has traditionally been offered first to children and younger adults with severe disease who have a matched sibling. Older adults are not excluded automatically; the Mayo Clinic notes that eligibility depends on overall health and fitness rather than a fixed birthday, and reduced-intensity conditioning has widened the window. What teams assess is organ reserve: heart, lung, liver and kidney function, and the ability to withstand weeks of low counts and possible infection.

The third factor is donor availability. A fully matched brother or sister remains the preferred source for severe aplastic anemia, and when one exists the transplant conversation usually happens early. Without a sibling match, the team weighs an unrelated donor search against immunosuppressive therapy, and the sequence of treatments may change.

A fourth consideration, easy to overlook, is the type of marrow failure. In inherited syndromes such as Fanconi anemia, transplant is often considered because the condition carries a lifelong risk of progressing to leukemia, and because immunosuppressive medicines do not address a genetic cause. In those cases a sibling donor must also be tested for the same gene change, since a carrier’s cells would not solve the problem.

Put together, the person most often offered a transplant early is someone with severe or very severe marrow failure, a fit body, and a well-matched donor already identified. Every departure from that picture prompts a more individual discussion.

Bone marrow transplant disqualifications: who is usually asked to wait, and why?

People searching for what disqualifies you from a bone marrow transplant often expect a firm list. In practice there are very few absolute bars and many reasons to pause. The most common reason to hold off is that the disease is not severe enough to justify the risk. Moderate aplastic anemia with stable counts and no transfusion dependence is frequently observed or treated with medicines first, because the transplant carries its own dangers and the marrow sometimes recovers.

An active, uncontrolled infection is a near-universal reason to delay. Conditioning wipes out the white cells that would fight that infection, so teams insist on treating it first. Significant heart, lung, liver or kidney impairment can also push the balance toward alternatives, since these organs bear the brunt of conditioning and of the medicines used afterward. The Mayo Clinic lists poor organ function among the factors that can make a person a poor candidate for the intensive versions of the procedure.

Frailty, meaning limited ability to manage daily activities and recover from setbacks, weighs heavily regardless of chronological age. So does an unstable psychiatric condition or substance use that would make adherence to a demanding medication and follow-up schedule unsafe; teams raise this not as a judgment but because missing immunosuppressant doses after transplant can be life-threatening.

Then there is the absence of a suitable donor. For some people, particularly those from ethnic backgrounds under-represented on volunteer registries, a well-matched unrelated donor may not be found quickly. That does not end the conversation, because half-matched family donors and cord blood are increasingly used, but it can change the recommended first step.

Lastly, timing matters. Someone who has just started immunosuppressive therapy is generally given several months to see whether it works before a transplant is revisited. Being asked to wait is rarely a closed door; it is more often a decision to gather information, treat what can be treated, and reassess.

Transplant versus immunosuppressive therapy: how teams weigh the choice

For acquired severe aplastic anemia the two definitive paths are transplant and immunosuppressive therapy. The latter uses medicines, typically an antithymocyte globulin combined with a calcineurin inhibitor, that dampen the immune attack on the marrow and give surviving stem cells room to recover. The NHLBI describes immunosuppressants as a mainstay for people who cannot have a transplant or who do not have a matched donor. Which path is offered first depends on the factors already discussed, and the table below summarizes how teams commonly frame the trade-offs.

Consideration	Allogeneic transplant	Immunosuppressive therapy
What it does	Replaces failing stem cells with a donor’s	Calms the immune attack so the person’s own marrow can recover
Typical first-line group	Younger, fit patients with a matched sibling donor	Older patients, those without a sibling match, or those unfit for conditioning
Main early risks	Infection during low counts, graft failure, graft-versus-host disease	Infection, infusion reactions, kidney effects from long-term medicines
Relapse of marrow failure	Uncommon once engrafted	Possible; some people need repeat courses
Later clonal blood disorders	Risk largely removed with new marrow	Risk persists and requires ongoing monitoring
Time to know it is working	Weeks (engraftment)	Often 3–6 months for counts to respond

Two points deserve emphasis. First, these are not competing camps; many people receive immunosuppressive therapy first and a transplant later if counts do not recover, and the treating team plans for that sequence from the start. Second, the “relapse” and “later clonal disorders” rows explain why some teams lean toward transplant in young patients even when medicines might work: the transplant, if successful, addresses the marrow for the long run, whereas medicines control the condition but leave the original marrow, with its risks, in place.

No table can replace an individual discussion, and the right answer for one person can be wrong for another with almost identical numbers. The value of the comparison is in showing what the team is actually weighing.

How bone marrow donors are matched: HLA explained in plain language

Every cell in the body carries surface proteins called human leukocyte antigens, or HLA, which act like an identity badge the immune system reads to tell self from foreign. Matching a donor means finding someone whose badge is as close as possible to the recipient’s, so that the new immune system does not attack the recipient’s body and the recipient’s remaining immune cells do not reject the graft.

HLA is inherited as two sets, one from each parent, which is why full siblings are the first place to look. Each brother or sister has roughly a one-in-four chance of matching, as the NHS notes in its guidance on stem cell transplants. Parents and children share only half their HLA with a patient, which makes them half-matched, or haploidentical, rather than full matches.

Testing is done from a blood sample or cheek swab and reads the DNA sequence of the key HLA genes. Laboratories describe the result as a fraction: how many of the compared markers match. Higher-resolution typing looks not just at the broad type of each marker but at the precise variant, because two people can appear matched on a coarse test and differ at a level the immune system still notices. Beyond HLA, teams also check blood group, cytomegalovirus exposure and, when several suitable donors exist, tend to prefer younger donors and consider sex and body size.

When no relative matches, the search moves to volunteer registries, national and international databases of people who have agreed to donate. Because HLA types cluster within ancestral populations, a person’s chance of finding an unrelated match depends partly on how well their background is represented in those registries. This is a known inequity and one reason registries actively recruit donors from under-represented communities.

The practical upshot for a patient: expect the team to type siblings first, then widen the search. The process has a logic, and the logic is the immune system’s own.

Sibling, unrelated, haploidentical and cord blood donors: what the options mean

Donor sources are usually presented in a preferred order, though the gaps between them have narrowed. A fully matched sibling has long been the standard for severe aplastic anemia because the immune systems are so alike that graft-versus-host disease and graft failure are less frequent. When one is found, the team may move quickly toward transplant rather than starting medicines first.

A matched unrelated donor is the next option, identified through registries. These transplants have become far safer over time thanks to high-resolution typing and better supportive care, and for some patients without a sibling they are now considered early rather than only after medicines fail. The search itself can take weeks to months, which is one reason a temporary course of immunosuppressive therapy or supportive transfusions may bridge the gap.

Haploidentical transplants use a half-matched relative, most often a parent, child or sibling. The mismatch would once have made rejection and severe graft-versus-host disease very likely, but a technique that gives a specific chemotherapy drug shortly after infusion to remove the most reactive donor immune cells has made these transplants a real option. Nearly everyone has at least one half-matched relative, which has changed the picture for people who previously had no donor.

Umbilical cord blood, collected after a baby’s birth and stored in public banks, contains stem cells that tolerate a degree of mismatch. Cord units hold a limited number of cells, so they are used more often in children and smaller adults, and engraftment tends to be slower.

How the cells are collected also varies. Marrow is drawn from the donor’s pelvic bone under anesthesia; peripheral blood stem cells are gathered from a vein after a few days of injections that coax cells into the bloodstream. For aplastic anemia, many teams prefer marrow as the source because it appears to carry a lower risk of chronic graft-versus-host disease, though the choice is individual.

What happens to the donor, and is it safe?

Prospective donors often ask two questions: will it hurt, and will it harm me? The honest answers are “somewhat, for a short time” and “serious harm is rare.” Donors first undergo a health assessment, including blood tests for infections and a review of their own medical history, because a donor’s safety is protected as carefully as the recipient’s.

If marrow is collected, the donor has a general or spinal anesthetic and a needle is passed through the skin into the back of the pelvic bone several times to draw liquid marrow. MedlinePlus describes this as a procedure done in an operating room, usually with the donor going home the same day or after one night. Afterward the lower back typically feels bruised and sore for several days to a couple of weeks, and fatigue is common because a meaningful volume of blood has been removed. The body replaces the marrow within a few weeks.

If peripheral blood stem cells are collected, the donor receives daily injections of a growth factor for a few days to move stem cells from the marrow into the bloodstream. This often causes bone aches, headache and flu-like tiredness while the injections continue. The collection itself, called apheresis, involves sitting for several hours while blood is drawn from one arm, passed through a machine that separates out the stem cells, and returned through the other arm. Tingling around the lips from the anticoagulant used in the machine is common and passes quickly.

Related donors sometimes feel pressure or guilt, particularly if the transplant later runs into trouble. Good programs offer donors their own advocate and separate consent process, and it is entirely appropriate for a potential donor to ask for time, ask about risks, or decline. A donor’s decision is meant to be free, and the team will not share a family member’s hesitation as a fault.

Conditioning: what happens in the days before the cells arrive

Conditioning is the treatment given in the days before infusion, and for many patients it is the hardest physical stretch of the whole process. Its purposes are to suppress the recipient’s immune system so the donor cells are not rejected and, in marrow failure, to clear residual abnormal cells and make room in the marrow. Because there is no cancer to eradicate in aplastic anemia, conditioning is often less intense than in leukemia transplants, but it still relies on chemotherapy and sometimes a low dose of total-body radiation.

The specific regimen depends on the diagnosis, the donor type and the patient’s age and fitness. Teams describe conditioning as myeloablative, meaning strong enough to wipe out the marrow, or reduced-intensity, meaning enough to suppress the immune system while leaving more of the body’s reserves intact. Reduced-intensity approaches have made transplant possible for older or less robust patients who would not have been candidates a generation ago.

What patients notice first is usually nausea, loss of appetite and profound tiredness. Mouth and gut lining cells are fast-dividing and take a hit from chemotherapy, so mouth soreness and diarrhea are common. Hair loss follows within a couple of weeks. A central venous catheter, a soft tube placed into a large vein in the chest, is used throughout for blood draws, medicines and the infusion itself, which spares the arms from repeated needles.

Fertility deserves a frank conversation before conditioning starts, because several of the drugs involved can permanently damage eggs and sperm. Options such as sperm banking or egg or embryo freezing exist but must be arranged in advance, and the team’s fertility counselor, not this article, is the right source of individual advice.

Conditioning is also when isolation precautions begin in earnest: a single room, filtered air, careful hand hygiene for every visitor, and restrictions on fresh flowers and certain foods. It feels strange at first and quickly becomes routine.

Bone marrow transplant recovery timeline: the first weeks after infusion

Day zero, the infusion, tends to be anticlimactic. The bag of cells is hung, sometimes with a preservative that gives off a faint garlic or creamed-corn smell that others in the room may notice, and it runs in over an hour or so. Then the waiting begins.

The first two to three weeks are the aplastic phase: the old marrow is gone and the new one has not yet started producing. White cells are close to zero, so infection is the dominant risk and daily blood tests, protective antibiotics and antifungals, and a low threshold for treating fever become the rhythm of the ward. Platelets and red cells are transfused as needed. Mouth soreness from conditioning usually peaks around this time and then improves.

Engraftment is declared when the neutrophil count rises above a threshold and stays there for three consecutive days. MedlinePlus gives a typical window of 10 to 28 days for new cells to begin appearing, with marrow grafts and cord blood tending toward the later end and peripheral blood stem cells toward the earlier. Platelets often recover more slowly than neutrophils and may need transfusion support for weeks afterward.

Many people go home once they are engrafted, eating and drinking, free of fever and able to take their medicines by mouth. The NHS notes that hospital stays commonly run several weeks, and that patients then need to live within easy reach of the transplant unit with frequent clinic visits, sometimes several times a week at first. A caregiver at home is not optional in most programs; someone must be able to monitor temperature, manage a complex medicine schedule and drive to the clinic at short notice.

Energy returns unevenly. A good day is followed by two flat ones. That pattern is normal, and clinicians often tell patients to measure progress week to week rather than day to day.

What happens 60 days after a bone marrow transplant, and at 100 days?

Around day 60 most people are at home, engrafted and beginning to feel like themselves for stretches of the day. It is also a point where the risks quietly shift rather than disappear. The new immune system is present but immature; it can produce neutrophils, yet the lymphocytes that remember and target specific viruses take far longer to mature. Cytomegalovirus reactivation is a particular concern in this window, which is why blood is tested for the virus regularly and antiviral medicine is started if it appears.

Acute graft-versus-host disease, if it is going to happen, usually shows itself in this first stretch after engraftment. It is the donor immune cells recognizing the recipient’s skin, gut or liver as foreign. Teams watch for a new rash, watery diarrhea or a rise in liver tests, and they adjust the immunosuppressant medicines accordingly. A degree of mild GVHD is common; severe forms are less so, and matching, marrow as the cell source, and modern prevention strategies all aim to reduce it.

A chimerism test is often performed around this time. It measures what proportion of the blood cells now carry the donor’s DNA rather than the recipient’s. Rising or fully donor chimerism is reassuring; falling donor chimerism can be an early warning of graft failure and prompts a discussion about options.

Day 100 is a conventional milestone, described by Johns Hopkins and other centers as the end of the highest-risk early period. Many programs mark it with a restaging visit, a repeat marrow biopsy and a gradual loosening of restrictions. It is not a finish line. Immunosuppressants continue for months, the risk of chronic GVHD and late infections persists, and the NHS notes that full recovery of the immune system can take a year or more. Vaccinations are typically restarted on a schedule the team sets, because the new immune system has no memory of childhood immunizations.

Risks in neutral terms: infection, graft failure and graft-versus-host disease

Any honest explainer has to put the risks in the same plain language as the benefits. Three stand out.

Infection is the most immediate. With no functioning white cells for weeks, bacteria that normally live harmlessly on the skin or in the gut can cause bloodstream infections, and fungi in the environment can cause pneumonia. Protective medicines, filtered rooms and rapid treatment of fever have made these far more manageable than in earlier decades, but they remain the reason for the strict early precautions.

Graft failure means the donor cells do not engraft, or engraft and then are lost. It is more common in aplastic anemia than in leukemia transplants, partly because heavily transfused patients may have developed antibodies against donor tissue and partly because the recipient’s immune system is not being weakened by disease in the same way. Teams reduce this risk by limiting transfusions before transplant where possible, matching carefully and tailoring conditioning. When it happens, options include a second infusion of cells or a repeat transplant.

Graft-versus-host disease comes in acute and chronic forms. The acute form, discussed above, affects skin, gut and liver in the early months. Chronic GVHD can appear later, sometimes after immunosuppressants are tapered, and can affect skin, mouth, eyes, joints, lungs and other organs in ways that range from a nuisance to a serious long-term condition. Because there is no cancer to fight in marrow failure, teams try particularly hard to prevent GVHD; its “graft-versus-leukemia” benefit does not apply here.

Beyond these, conditioning carries organ toxicity, infertility and a long-term rise in the risk of second cancers, and the months of immunosuppression bring their own side effects. The Mayo Clinic’s overview lists these frankly, and a good consent discussion will too. Risks are real, quantified for each individual, and weighed against the very real dangers of untreated severe marrow failure.

Stem cell transplant survival by age: why a single number misleads

People understandably search for survival rates by age, and it is worth being honest about why this article does not print one. Published outcomes vary enormously depending on the diagnosis, how severe the marrow failure is, how many transfusions preceded transplant, the donor type, the conditioning used, the era in which patients were treated and the way outcome is defined. A figure lifted from one cohort and applied to a different person is more likely to mislead than inform.

Age is a genuine factor. Studies of aplastic anemia consistently find that younger patients, particularly children and adults under about forty, tolerate transplant with fewer serious complications than older adults, which is the main reason age features so prominently in eligibility discussions. What has changed is that the gap has narrowed as conditioning has become gentler, matching more precise and supportive care better. Older age today is a reason for a more careful assessment, not an automatic exclusion.

The other thing a bare percentage hides is what is being counted. Overall survival, survival free of graft failure, survival free of chronic GVHD and quality of life are all different measures, and a treatment can look better on one and worse on another. The most useful comparison for an individual is the one the treating team can offer: how patients like this person, with this diagnosis, this donor and this conditioning plan, have fared at this program, alongside how the same kind of patient tends to do with the alternative.

Ask for that comparison directly. A team that answers with ranges, caveats and a discussion of what drives the differences is giving you better information than a single confident number would. Registries and consortia publish outcome data, and your team can point you toward the analyses most relevant to your situation.

What people often get wrong about transplant for marrow failure

The first misconception is that transplant is surgery. The recipient has no operation; the cells are infused through a catheter. The only person who might have a procedure under anesthesia is a donor giving marrow, and even that is a needle collection rather than an incision.

The second is that marrow failure is a cancer and the transplant is chemotherapy to kill it. Aplastic anemia is a failure of production, not a malignancy. Conditioning chemotherapy is used to suppress the immune system and make room, which is why it is often gentler than the regimens used for leukemia. Some inherited syndromes do carry a raised risk of later blood cancers, and that risk is one reason transplant is considered, but it is a different question.

Third, people assume a perfect match is required or nothing can be done. Half-matched relatives and cord blood have made it possible to find a donor for most people, and the choice among sources is now a nuanced discussion rather than a search for the one acceptable donor.

Fourth, families sometimes believe that being a donor means giving up a bone, or that donating harms fertility or long-term health. Marrow regenerates within weeks, and the growth factor injections used for blood collection have not been shown to cause lasting harm in healthy donors.

Fifth, there is a belief that day 100 means recovery is complete. It marks the end of the highest-risk window, but immune recovery, medicine tapering and the possibility of chronic GVHD extend well beyond it.

Finally, many assume that being told to wait means being turned down. It usually means the team wants to treat an infection, see whether medicines work, or complete a donor search. The door in marrow failure care is rarely shut; it is more often held open while the picture clarifies.

Questions to ask your care team

Consultations move quickly and it is easy to leave with the sense that something important went unasked. Writing questions down beforehand helps, and so does bringing someone to take notes. The following are the questions transplant teams say they wish more patients raised.

• How severe is my marrow failure by the criteria you use, and what does that mean for the urgency of a decision?
• Am I being considered for transplant first, or for immunosuppressive therapy first, and what would make you change that order?
• Which of my relatives will be tested, and if none match, how long does an unrelated donor search typically take in my situation?
• Would a half-matched relative or cord blood be an option for me, and how do you weigh those against waiting for an unrelated match?
• What conditioning regimen are you proposing, why that one, and what are its specific short- and long-term effects, including on fertility?
• How do patients with my diagnosis, age and donor type tend to do at this program, and how does that compare with the alternative you would offer?
• What is the plan if the graft fails or if graft-versus-host disease develops?
• What will my caregiver need to do, and for how long will I need to live near the unit?
• Which of my current medicines and supplements should I discuss with you before anything starts?
• Who do I call, at any hour, if I am worried?

Notice that several of these questions are about process rather than outcome. Knowing who to call and what the fallback plan is often does more for a person’s peace of mind than any statistic. A good team welcomes the list, and the answers will belong to your situation rather than to a general article.

When to call your doctor

Marrow failure, before or after transplant, leaves the body with little reserve, so symptoms that would be minor in someone with normal counts can escalate quickly. Transplant programs give every patient a direct number for this reason, and the instruction is always the same: call first, do not wait to see if it settles.

Contact the team urgently for a temperature at or above the threshold they have given you, or for chills and shaking even without a measured fever, because a fever in a person with few white cells is treated as a possible bloodstream infection until proven otherwise. Call for any bleeding that does not stop with gentle pressure within a few minutes, blood in urine or stool, black stools, a sudden crop of tiny red or purple spots on the skin, or a severe headache with confusion or vision changes, which can signal bleeding when platelets are low.

After transplant, report a new rash, especially on the palms, soles or ears; watery diarrhea several times a day; yellowing of the skin or eyes; or dark urine, since these can be early signs of graft-versus-host disease or liver trouble. Shortness of breath, a new cough, or chest pain need same-day attention. So do redness, swelling or discharge around the central line, and any new mouth sores that stop you drinking.

Seek emergency care immediately, calling emergency services, for difficulty breathing, fainting, uncontrolled bleeding, a seizure, or sudden weakness or trouble speaking.

Less dramatic changes still deserve a call: persistent nausea that prevents you from taking medicines, an inability to keep fluids down, or a general sense that something is wrong. Transplant teams would far rather hear about a false alarm than learn about a real one late. Whatever the symptom, the decision about what it means and what to do next belongs to the clinicians who know your case.

Frequently asked questions

What disqualifies you from a bone marrow transplant for marrow failure?

Absolute disqualifications are rare; more often a person is asked to wait. Reasons for delay include an active uncontrolled infection, significant heart, lung, liver or kidney impairment, frailty that would make recovery unsafe, marrow failure that is not yet severe enough to justify the risk, or the lack of a suitable donor. Teams reassess as infections clear, medicines are tried and donor searches progress, so a pause is not usually a final answer.

How are bone marrow donors matched to a patient?

Donors are matched by comparing HLA markers, inherited proteins the immune system uses to distinguish self from foreign. A blood or cheek sample is typed at the DNA level and compared with the patient’s. Full siblings are tested first because each has about a one-in-four chance of matching; if none does, volunteer registries are searched, and half-matched relatives or cord blood are considered when no full match is found.

What is the bone marrow transplant recovery timeline for aplastic anemia?

Conditioning takes several days before infusion, then a two-to-four-week hospital stay through the low-count phase until engraftment, which MedlinePlus places at roughly 10 to 28 days. Most people go home once engrafted but attend clinic several times a week initially. Day 100 marks the end of the highest-risk early period, and the NHS notes that immune recovery can take a year or more, with medicines tapered gradually over that time.

What happens 60 days after a bone marrow transplant?

By day 60 most patients are home and engrafted, with neutrophils recovering while deeper immune function remains immature. This is a key window for viral reactivation, particularly cytomegalovirus, and for acute graft-versus-host disease affecting skin, gut or liver, so blood tests are frequent and immunosuppressants are adjusted as needed. A chimerism test often checks what proportion of blood cells are now donor-derived.

Is there a stem cell transplant survival rate by age I can rely on?

No single figure applies to an individual. Outcomes depend on diagnosis, disease severity, prior transfusions, donor type, conditioning intensity and treatment era, not age alone. Younger patients do tend to have fewer serious complications, which is why age features in eligibility, but the gap has narrowed with gentler conditioning. Ask your team how patients with your specific profile have fared, and how that compares with the alternative treatment.

Can a parent or child be a bone marrow donor?

Yes, as a half-matched, or haploidentical, donor. Parents and children share exactly half their HLA markers with a patient, so they are never full matches, but modern techniques that remove the most reactive donor immune cells shortly after infusion have made half-matched transplants a realistic option. Nearly everyone has at least one such relative, which has widened access for people without a sibling or registry match.

Does donating bone marrow hurt or cause lasting harm?

Marrow donation is done under anesthesia, so the collection itself is not felt, but the lower back is typically sore and bruised for several days to a couple of weeks and fatigue is common. Peripheral blood donation involves a few days of growth factor injections that cause bone aches and flu-like tiredness, followed by a several-hour apheresis session. Marrow regenerates within weeks, and serious complications in healthy donors are rare.

Is bone marrow failure the same as bone marrow cancer, and what are the symptoms of bone marrow cancer?

No. Marrow failure means the marrow has stopped producing enough blood cells; marrow cancers such as leukemia or myeloma involve abnormal cells multiplying out of control. Both can cause tiredness, infections and bruising because they lower normal counts, which is why blood tests and a marrow biopsy, not symptoms alone, distinguish them. Anyone worried about persistent fatigue, unexplained bruising or repeated infections should see a doctor for evaluation.

Why might a transplant be preferred over medicines for a young person with aplastic anemia?

Immunosuppressive medicines can restore counts, but the original marrow remains, and with it the possibility of relapse and of later clonal blood disorders that need lifelong monitoring. A successful transplant replaces that marrow entirely. For a young, fit person with a matched sibling, teams often judge that the up-front risks of transplant are outweighed by these long-term considerations, though the decision is always individual.

What is conditioning, and is it always intensive?

Conditioning is the chemotherapy, sometimes with low-dose radiation, given in the days before infusion to suppress the immune system and make room for donor cells. Because marrow failure is not a cancer, conditioning is often less intense than in leukemia transplants, and reduced-intensity regimens have made transplant possible for older or less robust patients. Side effects commonly include nausea, mouth soreness, hair loss and effects on fertility.

References

• MedlinePlus: Bone marrow transplant
• NHS: Stem cell and bone marrow transplants

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.